Copay help by condition · Heart and circulation · read 2026-11-08
Pulmonary Hypertension: which charitable copay funds are open
2 funds for Pulmonary Hypertension say it is open right now, of the 2 we hold (read 2026-11-08).
Open: Pulmonary Hypertension - Medicare Access from HealthWell Foundation and Pulmonary hypertension from TotalAssist (Patient Advocate Foundation copay funds). Eligibility is each fund's own rule.
If you have Medicare Part D: CMS prints the annual out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026) (Table V-2 of its CY 2027 announcement). It is a benefit parameter and applies to covered drugs under plan rules. What changes on January 1.
Swipe to read across
A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.
Every fund we hold for Pulmonary Hypertension
- OpenPulmonary Hypertension - Medicare Access
HealthWell Foundation ·
Award level: not statedInsurance supported: not stated
The page lists the fund as Open. Source page
- OpenPulmonary hypertension
TotalAssist (Patient Advocate Foundation copay funds) ·
Award level: $9,500Insurance supported: Any health insurance
The page lists the fund as Open. Source page
Drugs whose FDA label names Pulmonary Hypertension
2 drugs. Each row quotes the sentence of the drug's FDA label (Indications and Usage, openFDA) that names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you. Dashes in quotes are shown as hyphens. Of these, 1 has a program (in our assistance finder or on the program's own page) and 0 have a Medicare negotiated price in the CMS file; an empty cell says we found nothing in our data, not that nothing exists.
| Drug | What the FDA label says | Manufacturer program | Medicare negotiated price |
|---|---|---|---|
| Adempas Riociguat Every route for this drug | Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. Label on openFDA, read 2026-11-10 | Bayer US Patient Assistance Foundation (program page) | not in the CMS negotiated-price file |
| Tyvaso Dpi Treprostinil | Pulmonary hypertension associated with interstitial lung disease (PH-ILD; Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
Related conditions
Group: Heart and circulation. All conditions: the condition index. Fund board for every condition: charitable copay fund status.
What changed
First read on 2026-11-08. We keep each read with its date, so a fund reopening or closing will show here as a change. Until we have a second read there is nothing to compare, and we do not guess. The read date of every source is on the changes page.
This page as data
The same facts as JSON, each fund with its source URL and read date: pulmonary-hypertension.json. Edition 2026-11, root 006ab9a329709cbe. See the licence page.
Questions
Is there an open charitable copay fund for Pulmonary Hypertension?
As read on 2026-11-08, 2 of the 2 funds we hold for Pulmonary Hypertension say they are open: Pulmonary Hypertension - Medicare Access from HealthWell Foundation and Pulmonary hypertension from TotalAssist (Patient Advocate Foundation copay funds). Funds open and close, so check the source page before you apply.
Which organizations run funds for Pulmonary Hypertension?
HealthWell Foundation and TotalAssist (Patient Advocate Foundation copay funds). Each fund row on this page links to the organization's own page.
Does an open fund mean I qualify?
No. A status says whether a fund is taking applications. Eligibility, award level and which insurance it supports are each fund's own rules; where the page states them they are shown on the fund.
How current is this page?
Statuses are what each fund's own page said on the date we read it (2026-11-08). We do not promise a fund is still in that state today.